STOCK TITAN

Vanda Pharmaceuticals (VNDA) SEC Filings, Jan-Feb 2026

VNDA NASDAQ

Vanda Pharmaceuticals Inc. filings document the company's operating results, commercial product disclosures, regulatory developments, and public-company governance. Form 8-K reports include quarterly and annual financial results, product-related events for NEREUS and BYSANTI, clinical and regulatory forward-looking language, and management communications about commercial strategy.

The company's proxy and governance filings cover director elections, board composition, executive compensation, equity awards, annual bonus and salary decisions, and related stockholder voting matters. Other current reports document board expansion, officer changes, compensatory arrangements, exhibits to press releases, and risk-oriented disclosures tied to Vanda's marketed products and development pipeline.

Rhea-AI Summary

Wijkstrom Joakim reported acquisition or exercise transactions in this Form 4 filing.

Vanda Pharmaceuticals senior vice president and chief marketing officer Joakim Wijkstrom received an equity grant covering 125,000 shares of common stock in the form of time-based restricted stock units (RSUs). These RSUs vest in four equal annual installments starting on March 1, 2027, contingent on his continued employment through each vesting date. After this award, his directly held common stock (including RSU-related shares as reported) totals 364,269 shares. The grant was recorded at a price of $0.00 per share, reflecting that it is a compensation award rather than an open-market purchase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
insider
-
Rhea-AI Summary

Birznieks Gunther reported acquisition or exercise transactions in this Form 4 filing.

Vanda Pharmaceuticals senior vice president of business development Gunther Birznieks reported an equity award in the form of 125,000 shares of common stock underlying a time-based restricted stock unit (RSU) grant. The RSUs vest in four equal annual installments, with the first vesting on March 1, 2027, as long as he remains continuously employed through each vesting date. Shares that vest will be delivered on the first permissible trading day defined in the RSU agreement. Following this grant, his directly held common stock position is 536,628 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
insider
-
Rhea-AI Summary

Williams Timothy reported acquisition or exercise transactions in this Form 4 filing.

Vanda Pharmaceuticals senior executive Timothy Williams received an equity award of 125,000 shares of common stock in the form of restricted stock units. These RSUs are scheduled to vest in four equal annual installments starting on March 1, 2027, contingent on his continued employment through each vesting date. After this grant, his directly held common stock reported in this filing totals 419,884 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
insider
Rhea-AI Summary

Vanda Pharmaceuticals Inc. reported that SVP, CFO & Treasurer Kevin Patrick Moran acquired 125,000 shares of common stock on February 18, 2026 through a time-based restricted stock unit (RSU) award granted at a price of $0.00 per share. The RSU represents common stock that will vest in four equal annual installments, with the first vesting on March 1, 2027, as long as he remains continuously employed through each vesting date. After this grant, he directly owns 453,822 shares of common stock, and there are an additional 635 shares reported as indirectly owned by his wife.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
insider
-
Rhea-AI Summary

Polymeropoulos Mihael Hristos reported acquisition or exercise transactions in this Form 4 filing.

Vanda Pharmaceuticals President and CEO Mihael Hristos Polymeropoulos received an equity grant of 525,000 shares of common stock in the form of time-based restricted stock units. The award was recorded at a price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.

The RSUs vest in four equal annual installments, with the first vesting date on March 1, 2027, as long as he remains continuously employed through each vesting date. Following this grant, his directly held common stock position is reported as 2,860,731 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
insider
-
Rhea-AI Summary

Vanda Pharmaceuticals detailed new pay and equity awards for its senior executives. The compensation committee granted 2025 cash bonuses, including $834,326 for CEO Mihael Polymeropoulos and amounts in the low $270,000 range for several other named officers.

For 2026, the CEO’s base salary was set at $994,625 with a target bonus of 80% of salary, while other named executives will earn base salaries of about $576,735–$596,990 with 45% bonus targets. The committee also granted substantial equity: the CEO received 525,000 RSUs and 175,000 target PSUs, and each other named officer received 125,000 RSUs and 40,000 target PSUs.

RSUs vest in four equal annual installments starting March 1, 2027. PSUs pay out between 50% and 150% of target based on relative total shareholder return versus the Nasdaq Biotechnology Index between December 31, 2025 and December 31, 2028, with any earned PSUs vesting on March 1, 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
current report
Rhea-AI Summary

Vanda Pharmaceuticals Inc. has filed a shelf registration to offer up to $200,000,000 of securities. The company may, from time to time, sell common stock, preferred stock, debt securities, warrants or units in one or more offerings, with terms set in future supplements.

The securities may be sold directly, through agents, or via underwriters, and net proceeds are intended for general corporate purposes. Vanda’s common stock trades on the Nasdaq Global Market under the symbol VNDA, with a last reported sale price of $7.43 per share on February 11, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.63%
Tags
registration
-
Rhea-AI Summary

Vanda Pharmaceuticals Inc. files its annual report outlining 2025 product sales and a broad late-stage pipeline. The company generated 2025 net sales of $117.3 million from Fanapt, $71.4 million from HETLIOZ, $27.4 million from PONVORY, and no reported U.S. sales yet for its newly approved motion sickness drug.

Vanda markets four commercial products and is advancing multiple late-stage programs, including an NDA for milsaperidone in bipolar I disorder and schizophrenia, an NDA for tradipitant in gastroparesis, and a BLA for imsidolimab in generalized pustular psoriasis. The company faces significant risks from generic HETLIOZ competition, complex FDA interactions on several indications, reliance on a few major customers, and extensive patent and regulatory litigation while pursuing global expansion and new indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.63%
Tags
annual report
-
Rhea-AI Summary

Vanda Pharmaceuticals reported full year 2025 total revenues of $216.1 million, up 9%, led by Fanapt net product sales of $117.3 million, a 24% increase. HETLIOZ and PONVORY sales declined modestly for the year.

GAAP net loss widened to $220.5 million from $18.9 million, driven largely by a one-time, non-cash income tax charge of $113.7 million related to a valuation allowance against deferred tax assets. Cash, cash equivalents and marketable securities were $263.8 million as of December 31, 2025.

Operationally, the FDA approved NEREUS (tradipitant) for prevention of motion-induced vomiting, while Bysanti (milsaperidone) has a PDUFA target action date of February 21, 2026 and an imsidolimab BLA for generalized pustular psoriasis was submitted. For 2026, Vanda projects total revenues of $230–$260 million, including Fanapt net product sales of $150–$170 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.63%
Tags
current report
Rhea-AI Summary

BlackRock Portfolio Management LLC has filed an amended Schedule 13G reporting a beneficial ownership stake in Vanda Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 3,251,563 shares, representing 5.5% of the class as of the event date 12/31/2025. BlackRock Portfolio Management LLC has sole voting power over 2,796,972 shares and sole dispositive power over 3,251,563 shares, with no shared voting or dispositive power.

The filing explains that the holdings are aggregated from certain BlackRock business units and are held in the ordinary course of business. It also certifies that the securities were not acquired for the purpose of changing or influencing control of Vanda Pharmaceuticals Inc., indicating a passive investment position under the Schedule 13G framework.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
ownership

FAQ

How many Vanda Pharmaceuticals (VNDA) SEC filings are available on StockTitan?

StockTitan tracks 69 SEC filings for Vanda Pharmaceuticals (VNDA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Vanda Pharmaceuticals (VNDA)?

The most recent SEC filing for Vanda Pharmaceuticals (VNDA) was filed on November 20, 2026.